Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.

[1]  S. Verstovsek,et al.  JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. , 2015, Blood.

[2]  M. Cazzola,et al.  Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. , 2015, Blood.

[3]  J. Smith-Gagen,et al.  Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011 , 2015, Journal of Cancer Research and Clinical Oncology.

[4]  M. Cazzola,et al.  Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project , 2014 .

[5]  V. Najfeld,et al.  MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. , 2014, Blood.

[6]  M. Heuser,et al.  Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation , 2014, Leukemia.

[7]  P. Guglielmelli,et al.  CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients , 2014, Leukemia.

[8]  N. Kröger,et al.  Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  F. Passamonti,et al.  CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons , 2014, Leukemia.

[10]  Alan M. Miller,et al.  Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[12]  T. Barbui,et al.  Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. , 2013, Blood.

[13]  B. Storer,et al.  Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  M. Minden,et al.  Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. , 2013, Blood.

[15]  A. Elmaagacli,et al.  Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis , 2012, Haematologica.

[16]  P. Hari,et al.  Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. , 2012, Blood.

[17]  H. Deeg,et al.  The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. , 2012, Blood.

[18]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[19]  Francisco Cervantes,et al.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.

[20]  J. Coffin,et al.  HIV reservoirs and the possibility of a cure for HIV infection , 2011, Journal of internal medicine.

[21]  R. Storb,et al.  Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60–78 years of age , 2011, British journal of haematology.

[22]  M. Griesshammer,et al.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Bernard,et al.  Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM‐TC) , 2011, British journal of haematology.

[24]  H. Deeg,et al.  Who is fit for allogeneic transplantation? , 2010, Blood.

[25]  Y. Hildebrandt,et al.  Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. , 2010, Blood.

[26]  M. Cazzola,et al.  Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. , 2010, Blood.

[27]  S. Verstovsek,et al.  Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  M. Cazzola,et al.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.

[29]  N. Kröger,et al.  Outcome of transplantation for myelofibrosis. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  G. Barosi,et al.  Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type , 2010, Bone Marrow Transplantation.

[31]  H. Einsele,et al.  Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2009, Blood.

[32]  H. Kantarjian,et al.  Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Fanin,et al.  Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) , 2008, Haematologica.

[34]  F. M. Stewart,et al.  Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  G. Barosi,et al.  Allogeneic hematopoietic stem cell transplantation for myelofibrosis , 2006, Current opinion in hematology.

[36]  R. Hoffman,et al.  Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. , 2005, Blood.

[37]  R. Mesa,et al.  Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. , 2005, Blood.

[38]  R. Hoover,et al.  Allelic frequency of a p53 polymorphism in human lung cancer. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.